R6152

Ranolazine dihydrochloride

≥98% (HPLC), powder, Na⁺-current blocker

• Synonim(y): (±) -4-[2-Hydroxy-3-(o-methoxyphenoxy)propyl]-1-piperazineaceto-2′,6′-xylidide dihydrochloride, N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide dihydrochloride
• Wzór empiryczny (zapis Hilla): C₂₄H₃₃N₃O₄ · 2HCl
• Numer CAS: 95635-56-6
• Masa cząsteczkowa: 500.46
• UNSPSC Code: 12352200
• PubChem Substance ID: 24278795
• NACRES: NA.77
• MDL number: MFCD03788770
• eCl@ss: 32039290
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Właściwości

• Nazwa produktu: Ranolazine dihydrochloride, ≥98% (HPLC), powder
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: white to beige
• mp: 222-229.5 °C (lit.)
• solubility: H₂O: soluble ≥10 mg/mL
• originator: Gilead
• SMILES string: Cl.Cl.COc1ccccc1OCC(O)CN2CCN(CC2)CC(=O)Nc3c(C)cccc3C
• InChI: 1S/C24H33N3O4.2ClH/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3;;/h4-10,20,28H,11-17H2,1-3H3,(H,25,29);2*1H
• InChI key: RJNSNFZXAZXOFX-UHFFFAOYSA-N
• Gene Information: human ... SCN4A(6329), SCN5A(6331)

Opis

Application

Ranolazine dihydrochloride has been used:

• as a low Torsades-de-pointes (TdP) risk drug to study its effects on QTc prolongation, electrocardiographic (PR and QRS) intervals in dog cardiovascular model
• as a partial fatty acid oxidation (FAO) inhibitor to study its effects on glioblastoma cells
• as a late sodium(Na⁺)-current (INaL) inhibitor to study its effects on atrial tachycardia in rabbit heart

Biochem/physiol Actions

Ranolazine is a derivative of anti-ischemic piperazine and acts as sodium (Na⁺)-current inhibitor. It has the potential to treat diastolic heart failure and helps in ameliorating myocardial diastolic function.

pFOX (partial fatty acid oxidation) inhibitor, a new class of anti-anginal drugs, which inhibit fatty acid beta-oxidation and activates pyruvate dehydrogenase, thereby diverting the heart′s energy source from lipids to glucose, which requires less oxygen and helps maintain myocardiac function at times of ischemia

Features and Benefits

This compound was developed by Gilead. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• WGK: WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable
• PPE (środki ochrony indywidualnej): Eyeshields, Gloves, type N95 (US)